CoChat
Sign Up
Cited by 77

HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis

Schuldenfrei, Andrew, Belton, Amy, Kowalski, Jeanne, Talbot, C Conover, Di Cello, Francescopaolo, Poh, Weijie, Tsai, Hua-Ling, Shah, Sandeep N +3 more·2011·BMC Genomics
DOI 10.1186/1471-2164-12-549PMC PMC3245506
Open this paper in CoChat — free account

Abstract

Background: Although the high mobility group A1(HMGA1) gene is widely overexpressed in diverse cancers and portends a poor prognosis in some tumors, the molecular mechanisms that mediate its role in transformation have remained elusive.HMGA1 functions as a potent oncogene in cultured cells and induces aggressive lymphoid tumors in transgenic mice. Because HMGA1 chromatin remodeling proteins regulate transcription,HMGA1 is thought to drive malignant transformation by modulating expression of specific genes. Genome-wide studies to define HMGA1 transcriptional networks during tumorigenesis, however, are lacking. To define the HMGA1 transcriptome, we analyzed gene expression profiles in lymphoid cells from HMGA1a transgenic mice at different stages in tumorigenesis. Results: RNA from lymphoid samples at 2 months (before tumors develop) and 12 months (after tumors are well-established) was screened for differential expression of > 20,000 unique genes by microarray analysis (Affymetrix) using a parametric and nonparametric approach. Differential expression was confirmed by quantitative RT-PCR in a subset of genes. Differentially expressed genes were analyzed for cellular pathways and functions using Ingenuity Pathway Analysis. Early in tumorigenesis, HMGA1 induced inflammatory pathways with NFkappaB identified as a major node. In established tumors, HMGA1 induced pathways involved in cell cycle progression, cell-mediated immune response, and cancer. At both stages in tumorigenesis, HMGA1 induced pathways involved in cellular development, hematopoiesis, and hematologic development. Gene set enrichment analysis showed that stem cell and immature T cell genes are enriched in the established tumors. To determine if these results are relevant to human tumors, we knocked-down HMGA1 in human T-cell leukemia cells and identified a subset of genes dysregulated in both the transgenic and human lymphoid tumors. Conclusions: We found that HMGA1 induces inflammatory pathways early in lymphoid tumorigenesis and pathways involved in stem cells, cell cycle progression, and cancer in established tumors.HMGA1 also dyregulates genes and pathways involved in stem cells, cellular development and hematopoiesis at both early and late stages of tumorigenesis. These results provide insight into HMGA1 function during tumor development and point to cellular pathways that could serve as therapeutic targets in lymphoid and other human cancers with aberrant HMGA1 expression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-2164-12-549

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • HMGA1 promotes an inflammatory transcriptional profile, at least in part by increasing Cox-2 and STAT-3 levels.

    “Particularly relevant to the role of miR-181 repression of HMGA1 in the inflammatory response, HMGA1 has been shown to promote an inflammatory transcriptional profile, at least in part by increasing Cox-2 and STAT-3 levels (Resar, 2010 for a review; Schuldenfrei et al., 2011).”

    From Evidence for miR‐181 involvement in neuroinflammatory responses of astrocytes (2013) · cites this paper as Schuldenfrei et al., 2011

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 78

  1. Ben-Porath I Thomson MW Carey VJ Ge R Bell GW Regev A Weinberg RA An embryonic stem cell-like signature in poorly differentiated aggressive tumors Nat Genetics 2008 40 5 499 507 10.1038/ng.127 PMC2912221 18443585 · DOI
  2. Wood LJ Mukherjee M Dolde CE Xu Y Maher JF Bunton TE Williams JB Resar LM HMG-I/Y: A new c-Myc target gene and potential oncogene Mol Cell Biol 2000 20 15 5490 5502 10.1128/MCB.20.15.5490-5502.2000 10891489 PMC86000 · DOI
  3. Wood LJ Maher JF Bunton TE Resar LMS The oncogenic properties of the HMG-I gene family Cancer Res 2000 60 15 4256 4261 10945639
  4. Pedulla ML Treff NR Resar LMS Reeves R Sequence and analysis of the murine Hmgiy (Hmga1) gene locus Gene 2001 27 1 51 58 11410365
  5. Dolde CE Mukherjee M Cho C Resar LMS HMG-I/Y in human breast cancer cell lines Breast Cancer Res Treat 2002 71 3 181 191 10.1023/A:1014444114804 12002338 · DOI
  6. Xu Y Sumter TF Bhattacharya R Tesfaye A Fuchs E Wood LJ Huso DL Resar LMS The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia Cancer Res 2004 64 10 3371 3375 10.1158/0008-5472.CAN-04-0044 15150086 · DOI
  7. Dhar A Hu J Reeves R Resar LMS Colburn NH Dominant negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation Oncogene 2004 23 25 4466 4476 10.1038/sj.onc.1207581 15064752 · DOI
  8. Hommura F Katabami M Leaner VD Donninger H Sumter TF Resar LMS Birrer MJ HMG-I/Y is a cJun/AP-1 target gene and is necessary for c-Jun induced anchorage-independent growth in Rat1a cells Mol Cancer Res 2004 2 5 303 314 15192124
  9. Takaha N Resar LMS Vindivich D Coffey DS HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells The Prostate 2004 60 2 160 167 10.1002/pros.20049 15162382 · DOI
  10. Hillion J Dhara S Sumter TF Di Cello FP Belton A Turkson J Jaganathan S Cheng L Ye Z Jove R Aplan P Lin YW Wertzler K Reeves R Elbahlouh O Kowalski J Bhattacharya R Resar LMS The high-mobility group A1a/Signal transducer and activator of transcription-3 axis: an "Achilles heel" for hematopoietic malignancies? Cancer Res 2008 68 24 10121 10127 10.1158/0008-5472.CAN-08-2121 19074878 PMC2913892 · DOI · Paper page
  11. Tesfaye A Di Cello FP Hillion J Ronnett BM Elbahloul O Ashfaq R Dhara S Prochownik E Roden R Tworkoski K Reeves R Roden R Hedrick Ellenson L Huso DL Resar LMS The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis Cancer Res 2007 67 9 3998 4004 10.1158/0008-5472.CAN-05-1684 17483309 · DOI
  12. Di Cello FP Hillion J Kowlaski J Ronnett BM Aderinto A Huso DL Resar LMS Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts Mol Cancer Ther 2008 7 7 2090 2095 10.1158/1535-7163.MCT-07-2282 18645019 PMC2593419 · DOI
  13. Hillion J Wood LJ Mukerjee M Bhattacharya R Di Cello F Kowalski J Elbahloul O Segal J Poirier J Rudin CM Dhara S Belton A Joseph B Zucker S Resar LMS Up-regulation of matrix metalloproteinase-2 by HMGA1 promotes transformation in undifferentiated, large cell lung cancer Mol Cancer Res 2009 7 11 1803 1812 10.1158/1541-7786.MCR-08-0336 19903768 PMC3069640 · DOI
  14. Hristov AC Cope L Di Cello FP Reyes MD Singh M Hillion JA Belton A Joseph B Schuldenfrei A Iacobuzio-Donahue CA Maitra A Resar LMS HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma Mod Pathol 2009 23 1 98 104 19820691 PMC3092591
  15. Belton A Gabrovsky A Bae YK Reeves R Iacobuzio-Donahue C Huso DL Resar LMS HMGA1 induces intestinal polyposis and drives tumor progression and stem cell properties in colon cancer cells PLoS ONE 2011 in press PMC3262796 22276142
  16. Resar LMS The High Mobility Group A1 Gene: Transforming inflammatory signals into cancer? Cancer Res 2010 70 2 436 439 10.1158/0008-5472.CAN-09-1212 20068164 PMC2807996 · DOI · Paper page
  17. Fusco A Fedele M Roles of HMGA proteins in cancer Nat Rev Cancer 2007 7 12 899 910 10.1038/nrc2271 18004397 · DOI
  18. Reeves R Edberg DD Li Y Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells Mol Cell Biol 2001 21 2 575 594 10.1128/MCB.21.2.575-594.2001 11134344 PMC86623 · DOI
  19. Reeves R Molecular biology of HMGA proteins: hubs of nuclear function Gene 2002 277 1-2 63 81 11602345
  20. Karp JE Smith BD Resar LMS Greer JM Blackford AL Zhao M Moton-Nelson D Alino K Levis MJ Gore SD Joseph B Carraway H McDevitt MA Bagain L Mackey K Briel J Blackford AL Doyle LA Wright JJ Rudek M Phase I and pharmacokinetic study of "hybrid" (bolus-infusion) flavopiridol administered followed in time sequence by cytosine arabinoside and mitoxantrone for adults with relapsed and refractory acute leukemias Blood 2011 117 12 3302 3310 10.1182/blood-2010-09-310862 21239698 PMC3069672 · DOI
  21. Nelson DM Joseph B Hillion J Segal J Karp JE Resar LMS Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in acute myeloid leukemia Leuk Lymphoma 2011 52 10 1999 2006 10.3109/10428194.2011.591012 21728742 PMC3214625 · DOI
  22. Dang CV Resar LMS Emison E Kim S Prescott JE Wonsey D Zellar K Function of the c-Myc oncogenic transcription factor Exp Cell Res 1999 253 1 63 77 10.1006/excr.1999.4686 10579912 · DOI
  23. Shah SN Resar LMS HMGA1 in Cancer: Potential biomarker & therapeutic target Histol Histopathol 2011 in press 22419021
  24. Johnson KR Lehn DA Elton TS Barr PJ Reeves R Complete murine cDNA sequence, genomic structure, and tissue expression of the high mobility group protein HMG-I(Y) J Biol Chem 1988 18 34 18338 18342 3192537
  25. Johnson KR Cook SA Davisson MT Chromosomal localization of the murine gene and two related sequences encoding high-mobility group I and Y proteins Genomics 1992 12 3 503 509 10.1016/0888-7543(92)90441-T 1559701 · DOI
  26. Hock R Furusawa T Ueda T Bustin M HMG chromosomal proteins in development and disease Trends Cell Biol 2007 17 2 72 79 10.1016/j.tcb.2006.12.001 17169561 PMC2442274 · DOI
  27. Lund T Holtlund J Fredriksen M Laland SG On the presence of two new high mobility group-like proteins in HeLa S3 cells FEBS Lett 1983 152 2 163 167 10.1016/0014-5793(83)80370-6 6297996 · DOI
  28. Di Cello F Hillion J Hristov A Wood LJ Mukherjee M Schuldenfrei A Kowalski J Bhattacharya R Ashfaq R Resar LM HMGA2 participates in neoplastic transformation in human lung cancer Mol Cancer Res 2008 6 5 743 750 10.1158/1541-7786.MCR-07-0095 18505920 PMC3086547 · DOI
  29. Hristov AC Cope L Reyes MD Singh M Iacobuzio-Donahue C Maitra A Resar LM HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma Mod Pathol 2009 22 1 43 49 10.1038/modpathol.2008.140 18843278 PMC2769577 · DOI
  30. Ikeda K Mason PJ Bessler M 3'UTR truncated HmgA2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice Blood 2011 117 22 5860 5869 10.1182/blood-2011-02-334425 21460244 PMC3112035 · DOI
  31. Resar L Brodsky R ΔHMGA2: "Let"ing go with clonal expansion? Blood 2011 117 22 5788 5790 10.1182/blood-2011-04-346668 21636715 · DOI
  32. Chiappetta G Avantaggiato V Visconti R Fedele M Battista S Trapasso F Merciai BM Fidanza V Giancotti V Santoro M Simeone A Fusco A High level expression of the HMGI (Y) gene during embryonic development Oncogene 1996 13 11 2439 2446 8957086
  33. Moliterno AR Resar LMS AKNA: Another AT-hook transcription factor "hooking-up" with inflammation Cell Res 2011 21 1528 1530 PMC3365640 21670742
  34. Fedele M Pantimalli F Baldassarre G Battista S Klein-Szanto AJ Kenyon L Visone R De Martino I Ciarmiello A Arra C Viglietto G Croce CM Fusco A Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas Oncogene 2005 24 21 3427 3435 10.1038/sj.onc.1208501 15735694 · DOI
  35. Scala S Portella G Fedele M Chiapetta G Fusco A Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias Proc Natl Acad Sci USA 2000 97 8 4256 4261 10.1073/pnas.070029997 10759549 PMC18219 · DOI
  36. Liau SS Jazag A Whang EE HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma Cancer Res 2006 66 24 11613 11622 10.1158/0008-5472.CAN-06-1460 17178855 · DOI
  37. Pomeroy SL Tamayo P Gaasenbeek M Sturla LM Angelo M McLaughlin ME Kim JY Goumnerova LC Black PM Lau C Allen JC Zagzag D Olson JM Curran T Wetmore C Biegel JA Poggio T Mukherjee S Rifkin R Califano A Stolovitzky G Louis DN Mesirov JP Lander ES Golub TR Prediction of central nervous system embryonal tumour outcome based on gene expression Nature 415 6870 436 442 11807556
  38. Flohr AM Rogalla P Bonk U Puettmann B Buerger H Gohla G Packeisen J Wosniok W Loeschke S Bullerdiek J High mobility group protein HMGA1 expression in breast cancer reveals a positive correlation with tumour grade Histol Histopathol 2003 18 4 999 1004 12973668
  39. Sarhadi VK Wikman H Salmenkivi K Kuosma E Sioris T Salo J Karjalainen A Knuutila S Anttila S Increased expression of high mobility group A proteins in lung cancer J Pathol 2002 209 2 206 212 16521118
  40. Chou BK Mali P Huang X Ye Z Dowey SN Resar LMS Tong J Cheng L Unique epigenetic signature of human blood cells permits efficient iPS cell derivation by a non-integrating plasmid Cell Research 2011 21 3 518 529 2011 10.1038/cr.2011.12 21243013 PMC3193421 · DOI
  41. Kowalski J Blackford A Feng C Mamelak AJ Sauder DN Nested, nonparametric, correlative analysis of microarrays for heterogenous phenotype characterization Statistics in Medicine 2007 26 5 1090 1101 10.1002/sim.2596 16817149 · DOI
  42. Sedaghat AR German J Teslovich TM Cofrancesco J Jr Jie CC Talbot CC Jr Siliciano RF Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics J Virol 2008 82 4 1870 1883 10.1128/JVI.02228-07 18077723 PMC2258719 · DOI
  43. Irizarry RA Bolstad BM Collin F Cope LM Hobbs B Speed TP Summaries of Affymetrix GeneChip probe level data Nucleic Acids Res 2003 31 4 e15 10.1093/nar/gng015 12582260 PMC150247 · DOI
  44. Irizarry RA Hobbs B Collin F Beazer-Barclay YD Antonellis KJ Scherf U Speed TP Exploration, normalization, and summaries of high density oligonucleotide array probe level data Biostatistics 2003 4 2 249 264 10.1093/biostatistics/4.2.249 12925520 · DOI · Paper page
  45. Pilon AM Arcasoy MO Dressman HK Vayda SE Maksimova YD Sangerman JI Gallagher PG Bodine DM Failure of Terminal Erythroid Differentiation in EKLF-Deficient Mice Is Associated with Cell Cycle Perturbation and Reduced Expression of E2F2 Mol Cell Biol 2008 28 24 7394 7401 10.1128/MCB.01087-08 18852285 PMC2593440 · DOI
  46. Mootha VK Lindgren CM Eriksson KF Subramanian A Sihag S Lehar J Puigserver P Carlsson E Ridderstråle M Laurila E Houstis N Daly MJ Patterson N Mesirov JP Golub TR Tamayo P Spiegelman B Lander ES Hirschhorn JN Altshuler D Groop LC PGC-1 alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes Nat Genet 2003 34 3 267 273 10.1038/ng1180 12808457 · DOI · Paper page
  47. Thanos D Maniatis T The high mobility group protein HMGI(Y) is required for NF-kappa B-dependent virus induction of the IFN-Beta gene Cell 1992 71 5 777 789 10.1016/0092-8674(92)90554-P 1330326 · DOI · Paper page
  48. Du W Thanos D Maniatis T Mechanisms of transcriptional synergism between distinct virus-inducible enhancer elements Cell 1993 74 5 887 898 10.1016/0092-8674(93)90468-6 8374955 · DOI
  49. Thanos D Du W Maniatis T The high mobility group protein HMG I(Y) is an essential structural component of virus-inducible enhancer complex Cold Spring Harbor Symp Quant Biol 1993 58 73 81 7956090
  50. Thanos D Maniatis T Virus induction of human IFN-Beta gene expression requires the assembly of an enhanceosome Cell 1995 83 7 1091 1100 10.1016/0092-8674(95)90136-1 8548797 · DOI · Paper page
  51. Falvo JV Thanos D Maniatis T Reversal of intrinsic DNA bends in the IFN-Beta gene enhancer by transcription factors and the architectural protein HMG I(Y) Cell 1995 83 7 1101 1111 10.1016/0092-8674(95)90137-X 8548798 · DOI
  52. Munshi N Agalioti T Lomvardas S Merika M Chen G Thanos D Coordination of transcriptional switch by HMGI(Y) acetylation Science 2001 293 5532 1133 1136 10.1126/science.293.5532.1133 11498590 · DOI
  53. Aggarwal BBP Gehlot P Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 2009 9 4 347 350 10.1016/j.coph.2009.06.018 19665429 PMC2730981 · DOI
  54. Dhanasekaran DN Johnson GL MAPKs: function, regulation, role in cancer and therapeutic targeting Oncogene 2007 26 22 3097 3099 10.1038/sj.onc.1210395 17496908 · DOI
  55. Trinchieri G Interleukin-12 and regulation of innate resistance and adaptive immunity Nature Reviews Immunology 2003 3 2 133 146 10.1038/nri1001 12563297 · DOI
  56. Pestka S Krause CD Sarkar D Walter MR Shi Y Fisher PB Interleukin-10 and related cytokines and receptors Ann Rev Immunol 2004 22 929 979 10.1146/annurev.immunol.22.012703.104622 15032600 · DOI
  57. Call ME Pyrdol J Wucherpfennig KW Stoichiometry of the T-cell receptor-CD3 complex and key intermediates assembled in the endoplasmic reticulum EMBO J 2004 23 12 2348 2357 10.1038/sj.emboj.7600245 15152191 PMC423287 · DOI
  58. Kastan MB Wild-type p53: tumors can't stand it Cell 2007 128 5 837 840 10.1016/j.cell.2007.02.022 17350571 · DOI
  59. Bloom J Cross FR Multiple levels of cyclin specificity in cell-cycle control Nature Rev Mol Cell Biol 2007 8 2 149 160 10.1038/nrm2105 17245415 · DOI
  60. Egloff AM Vella LA Finn OJ Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer Cancer Res 2006 66 1 6 9 10.1158/0008-5472.CAN-05-3389 16397206 · DOI
  61. Yang R Muller C Huynh V Fung YK Yee AS Koeffler HP Functions of cyclin A1 in the cell cycle and its interactions with transcription factor E2F-1 and the Rb family of proteins Mol Cell Biol 1999 19 3 2400 2407 10022926 PMC84032
  62. Dimova DK Dyson NJ The E2F1 transcriptional network: old aquaintances with new faces Oncogene 2005 24 17 2810 2826 10.1038/sj.onc.1208612 15838517 · DOI · Paper page
  63. Krug U Ganser A Koeffler HP Tumor suppressor genes in normal and malignant hematopoiesis Oncogene 2002 21 21 3475 3495 10.1038/sj.onc.1205322 12032783 · DOI
  64. Ishida T Inagaki H Utsunomiya A Takatsuka Y Komatsu H Iida S Takeuchi G Eimoto T Nakamura S Ueda R CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-Cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-Cell lymphoma, unspecified Clin Cancer Res 2004 10 16 5494 5500 10.1158/1078-0432.CCR-04-0371 15328188 · DOI
  65. Glinsky GV Death-from-cancer signature and stem cell contribution to metastatic cancer Cell Cycle 2005 4 9 1171 1175 10.4161/cc.4.9.2001 16082216 · DOI
  66. Glinsky GV Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway Cycle 2006 5 11 1208 1216 10.4161/cc.5.11.2796 16760651 · DOI
  67. Takemoto N Intlekofer AM Northrup JT Wherry EJ Reiner SL Cutting edge: IL-12 inversely regulates T-beta and eomesodermin expression during pathogen-induced CD8+ T cell differentiation J Immunol 2006 177 11 7515 7519 17114419
  68. Lei T Hohn HP Behr R Denker HW Influences of extracellular matrix and conditioned media on differentiation and invasiveness of trophoblast stem cells Placenta 2007 28 1 14 21 10.1016/j.placenta.2006.01.020 16563500 · DOI
  69. Takizawa F Araki K Ito K Moritomo T Nakanishi T Expression analysis of two Eomesodermin homologues in zebrafish lymphoid tissues and cells Mol Immunol 2007 44 9 2324 2331 10.1016/j.molimm.2006.11.018 17194477 · DOI
  70. Lee MS Hanspers K Barker CS Korn AP McCune JM Gene expression profiles during human CD4+ T cell differentiation Int Immunol 2004 16 8 1109 1124 10.1093/intimm/dxh112 15210650 · DOI
  71. Ramalho-Santos M Yoon S Matsukaki Y Mulligan RC Melton D "Stemness": transcriptional profiling of embryonic and adult stem cells Science 2002 298 5593 597 600 10.1126/science.1072530 12228720 · DOI
  72. de Groot D Haverslag RT Pasterkamp G de Kleijn DPV Hoefer IE Targeted deletion of the inhibitor NF-κB p50 subunit in bone-marrow-derived cells improves collateral growth after arterial occlusion Cardiovasc Res 2010 88 1 179 185 10.1093/cvr/cvq150 20495189 · DOI
  73. Atreya I Schimanski CC Becker C Wirtz S Dornhoff H Schnurer E Berger MR Galle PR Herr W Neurath MF The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer Gut 2007 56 11 1572 1578 10.1136/gut.2006.117812 17566017 PMC2095672 · DOI
  74. Pierantoni GM Battista S Pentimalli F Fedele M Visone R Federico A Santoro M Viglietto G Fusco A A truncated HMGA1 gene induces proliferation of the 3T3-L1 pre-adipocyte cells: a model of human lipomas Carcinogenesis 2003 24 12 1861 1869 10.1093/carcin/bgg149 12970064 · DOI
  75. Ueda Y Watanabe S Tei S Saitoh N Kuratsu J Nakao M High mobility group protein HMGA1 inhibits retinoblastoma protein-mediated cellular G0 arrest Cancer Sci 2007 98 12 1893 1901 10.1111/j.1349-7006.2007.00608.x 17877762 PMC11160013 · DOI
  76. Fedele M Fidanza V Battista S Pentimalli F Klein-Szanto AJ Visone R De Martino I Curcio A Morisco C Del Vecchio L Baldassarre G Arra C Viglietto G Indolfi C Croce CM Fusco A Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice Cancer Res 2006 66 5 2536 2543 10.1158/0008-5472.CAN-05-1889 16510570 · DOI
  77. Schmitt CA McCurrach ME de Stanchina E Wallace-Brodeur RR Lowe SW INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53 Genes Dev 1999 13 20 2670 2677 10.1101/gad.13.20.2670 10541553 PMC317110 · DOI · Paper page
  78. Cleveland JL Sherr CJ Antagonism of Myc functions by Arf Cancer Cell 2004 6 4 309 311 10.1016/j.ccr.2004.09.020 15488753 · DOI

Cited by

Sorted by citations

Authors
Schuldenfrei, A., Belton, A., Kowalski, J., Talbot, C. C., Di Cello, F., Poh, W., Tsai, H.-L., Shah, S. N., Huso, T. H., Huso, D. L., & Resar, L. M.
Venue
BMC Genomics
Publisher
Springer Science and Business Media LLC
Published
2011-11-04
Volume
12
Issue
1
ISSN
1471-2164
DOI
10.1186/1471-2164-12-549
PMC
PMC3245506
Cited by
77
References
2
Language
en
Licence
creativecommons.org/licenses/by/2.0 (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review